Financial Counselors Inc Astrazeneca PLC Transaction History

Financial Counselors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$76.67 - $87.62 $22,004 - $25,146	287 Added 4.38%	6,833 $532,000
Q2 2024 Aug 01, 2024	SELL	$66.81 - $80.83 $64,538 - $78,081	-966 Reduced 12.86%	6,546 $510,000
Q1 2024 May 02, 2024	SELL	$61.03 - $69.57 $488 - $556	-8 Reduced 0.11%	7,512 $508,000
Q4 2023 Jan 26, 2024	BUY	$61.89 - $69.28 $24,570 - $27,504	397 Added 5.57%	7,520 $506,000
Q3 2023 Nov 07, 2023	BUY	$64.85 - $71.7 $121,464 - $134,294	1,873 Added 35.68%	7,123 $482,000
Q2 2023 Jul 27, 2023	BUY	$69.91 - $75.81 $29,921 - $32,446	428 Added 8.88%	5,250 $376,000
Q1 2023 May 02, 2023	SELL	$63.15 - $71.6 $19,071 - $21,623	-302 Reduced 5.89%	4,822 $335,000
Q3 2022 Nov 01, 2022	BUY	$53.02 - $135.75 $271,674 - $695,583	5,124 New	5,124 $281,000
Q3 2017 Nov 13, 2017	SELL	$28.96 - $34.0 $198,984 - $233,614	-6,871 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	6,871	6,871 $234,000

1,368

475M

6.08M

4.44M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $226B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Financial Counselors Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Counselors Inc with notifications on news.